Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Cancer Res. 2018 Dec 11;79(3):546–556. doi: 10.1158/0008-5472.CAN-18-1492

Figure 1. ROS1 fusion partners dictate differential activation of downstream signaling pathways.

Figure 1.

(A) Diagram of the commonly occurring ROS1 fusion oncoproteins, which were studied here. Pink denotes a transmembrane domain. (B) Topological configuration of ROS1 fusions based on CCTOP computational analysis (28). (C) Immunoblot analysis of 293T cells transiently transfected for 48h with GFP, SDC4-ROS1, CD74-ROS1, or SLC34A2-ROS1, with 5h serum starvation. The pROS1 antibody used recognizes Y2274 of the full-length ROS1 protein. (D-G) Immunoblot analysis of patient-derived cell lines expressing (D) SDC4-ROS1, (E) SLC34A2-ROS1, or (F-G) CD74-ROS1 with siRNA-mediated knockdown of ROS1 (55h after transfection). Data shown in (C-G) are representative of ≥ 3 independent experiments.